Does not make any sense to wait until Flaskworks which will take another 18 months or more for commercial approval.
And there will be no special support for DCVAX-L outside NICE pathway except a couple of patients here and there. Didnt happen at Specials and will not happen at UK approvals. There are so many therapies that are approved by regulators and are novel, but have no reimbursement support. And some of these companies were forced to shut down because there was no viable path to revenue.
I am not saying NWBO will fail or go bankrupt, but it will not deserve market cap over a billion dollar without progress on reimbursement, particularly with the history of this management and all the manipulators against it over the years.
Market Data 
Markets 
AI
